Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial

Acute kidney injury independently predicts mortality in falciparum malaria. It is not known whether acetaminophen's capacity to inhibit plasma hemoglobin-mediated oxidation is renoprotective in severe malaria.A phase 2, open-label, randomized controlled trial at two hospitals in Bangladesh was...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Plewes, K, Kingston, HWF, Ghose, A, Wattanakul, T, Hassan, MMU, Haider, MS, Dutta, PK, Islam, MA, Alam, S, Jahangir, SM, Zahed, ASM, Sattar, MA, Chowdhury, MAH, Herdman, MT, Leopold, SJ, Ishioka, H, Piera, KA, Charunwatthana, P, Silamut, K, Yeo, TW, Lee, SJ, Mukaka, M, Maude, RJ, Turner, GDH, Faiz, MA, Tarning, J, Oates, JA, Anstey, NM, White, NJ, Day, NPJ, Hossain, MA, Roberts, LJ, Dondorp, AM
Format: Journal article
Język:English
Wydane: Oxford University Press 2018
_version_ 1826269955664904192
author Plewes, K
Kingston, HWF
Ghose, A
Wattanakul, T
Hassan, MMU
Haider, MS
Dutta, PK
Islam, MA
Alam, S
Jahangir, SM
Zahed, ASM
Sattar, MA
Chowdhury, MAH
Herdman, MT
Leopold, SJ
Ishioka, H
Piera, KA
Charunwatthana, P
Silamut, K
Yeo, TW
Lee, SJ
Mukaka, M
Maude, RJ
Turner, GDH
Faiz, MA
Tarning, J
Oates, JA
Anstey, NM
White, NJ
Day, NPJ
Hossain, MA
Roberts, LJ
Dondorp, AM
author_facet Plewes, K
Kingston, HWF
Ghose, A
Wattanakul, T
Hassan, MMU
Haider, MS
Dutta, PK
Islam, MA
Alam, S
Jahangir, SM
Zahed, ASM
Sattar, MA
Chowdhury, MAH
Herdman, MT
Leopold, SJ
Ishioka, H
Piera, KA
Charunwatthana, P
Silamut, K
Yeo, TW
Lee, SJ
Mukaka, M
Maude, RJ
Turner, GDH
Faiz, MA
Tarning, J
Oates, JA
Anstey, NM
White, NJ
Day, NPJ
Hossain, MA
Roberts, LJ
Dondorp, AM
author_sort Plewes, K
collection OXFORD
description Acute kidney injury independently predicts mortality in falciparum malaria. It is not known whether acetaminophen's capacity to inhibit plasma hemoglobin-mediated oxidation is renoprotective in severe malaria.A phase 2, open-label, randomized controlled trial at two hospitals in Bangladesh was conducted to assess effects on renal function, safety, pharmacokinetic properties and pharmacodynamic effects of acetaminophen. Febrile patients ( >12 years) with severe and moderately severe falciparum malaria were randomly assigned to receive acetaminophen (1g 6-hourly for 72 hours) or no acetaminophen, as an adjunct to intravenous artesunate. Primary outcome was the proportional change in creatinine after 72 hours stratified by median plasma hemoglobin.Between July 2012 and September 2014, 62 patients were randomly assigned to receive acetaminophen (n=31) or no acetaminophen (n=31). Median (interquartile range) reduction in creatinine after 72 hours was 23% (37 to 18%) in patients assigned to acetaminophen, versus 14% (29 to 0%) in patients assigned to no acetaminophen (p=0.043). This difference in reduction was 37% (48 to 22%) versus 14% (30 to -71%) in patients with plasma hemoglobin ≥45,000 ng/mL (p=0.010). The proportion of patients with progressing acute kidney injury was higher among controls (subdistribution hazard ratio, 3.0; 95% CI, 1.1 to 8.5; p=0.034). Pharmacokinetic-pharmacodynamic analyses showed that higher exposure to acetaminophen increased the probability of creatinine improvement. No patient fulfilled Hy's Law for hepatotoxicity.In this proof-of-principle study, acetaminophen showed renoprotection without evidence of safety concerns in patients with severe falciparum malaria, particularly in those with prominent intravascular hemolysis.
first_indexed 2024-03-06T21:33:17Z
format Journal article
id oxford-uuid:45647da0-731b-42c8-b699-2e2078183303
institution University of Oxford
language English
last_indexed 2024-03-06T21:33:17Z
publishDate 2018
publisher Oxford University Press
record_format dspace
spelling oxford-uuid:45647da0-731b-42c8-b699-2e20781833032022-03-26T15:07:43ZAcetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:45647da0-731b-42c8-b699-2e2078183303EnglishSymplectic Elements at OxfordOxford University Press2018Plewes, KKingston, HWFGhose, AWattanakul, THassan, MMUHaider, MSDutta, PKIslam, MAAlam, SJahangir, SMZahed, ASMSattar, MAChowdhury, MAHHerdman, MTLeopold, SJIshioka, HPiera, KACharunwatthana, PSilamut, KYeo, TWLee, SJMukaka, MMaude, RJTurner, GDHFaiz, MATarning, JOates, JAAnstey, NMWhite, NJDay, NPJHossain, MARoberts, LJDondorp, AMAcute kidney injury independently predicts mortality in falciparum malaria. It is not known whether acetaminophen's capacity to inhibit plasma hemoglobin-mediated oxidation is renoprotective in severe malaria.A phase 2, open-label, randomized controlled trial at two hospitals in Bangladesh was conducted to assess effects on renal function, safety, pharmacokinetic properties and pharmacodynamic effects of acetaminophen. Febrile patients ( >12 years) with severe and moderately severe falciparum malaria were randomly assigned to receive acetaminophen (1g 6-hourly for 72 hours) or no acetaminophen, as an adjunct to intravenous artesunate. Primary outcome was the proportional change in creatinine after 72 hours stratified by median plasma hemoglobin.Between July 2012 and September 2014, 62 patients were randomly assigned to receive acetaminophen (n=31) or no acetaminophen (n=31). Median (interquartile range) reduction in creatinine after 72 hours was 23% (37 to 18%) in patients assigned to acetaminophen, versus 14% (29 to 0%) in patients assigned to no acetaminophen (p=0.043). This difference in reduction was 37% (48 to 22%) versus 14% (30 to -71%) in patients with plasma hemoglobin ≥45,000 ng/mL (p=0.010). The proportion of patients with progressing acute kidney injury was higher among controls (subdistribution hazard ratio, 3.0; 95% CI, 1.1 to 8.5; p=0.034). Pharmacokinetic-pharmacodynamic analyses showed that higher exposure to acetaminophen increased the probability of creatinine improvement. No patient fulfilled Hy's Law for hepatotoxicity.In this proof-of-principle study, acetaminophen showed renoprotection without evidence of safety concerns in patients with severe falciparum malaria, particularly in those with prominent intravascular hemolysis.
spellingShingle Plewes, K
Kingston, HWF
Ghose, A
Wattanakul, T
Hassan, MMU
Haider, MS
Dutta, PK
Islam, MA
Alam, S
Jahangir, SM
Zahed, ASM
Sattar, MA
Chowdhury, MAH
Herdman, MT
Leopold, SJ
Ishioka, H
Piera, KA
Charunwatthana, P
Silamut, K
Yeo, TW
Lee, SJ
Mukaka, M
Maude, RJ
Turner, GDH
Faiz, MA
Tarning, J
Oates, JA
Anstey, NM
White, NJ
Day, NPJ
Hossain, MA
Roberts, LJ
Dondorp, AM
Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title_full Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title_fullStr Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title_full_unstemmed Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title_short Acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe Falciparum malaria: a randomized, controlled, open-label trial
title_sort acetaminophen as a renoprotective adjunctive treatment in patients with severe and moderately severe falciparum malaria a randomized controlled open label trial
work_keys_str_mv AT plewesk acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT kingstonhwf acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT ghosea acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT wattanakult acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT hassanmmu acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT haiderms acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT duttapk acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT islamma acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT alams acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT jahangirsm acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT zahedasm acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT sattarma acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT chowdhurymah acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT herdmanmt acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT leopoldsj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT ishiokah acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT pieraka acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT charunwatthanap acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT silamutk acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT yeotw acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT leesj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT mukakam acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT mauderj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT turnergdh acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT faizma acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT tarningj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT oatesja acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT ansteynm acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT whitenj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT daynpj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT hossainma acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT robertslj acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial
AT dondorpam acetaminophenasarenoprotectiveadjunctivetreatmentinpatientswithsevereandmoderatelyseverefalciparummalariaarandomizedcontrolledopenlabeltrial